📰 Cancer Sci News
Page 2 - Cancer Sci News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Cancer Sci. Real-time updates on events, politics, business and more.
November 3, 2022
Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody®-CD3xCD20) in a variety of treatment settings and hematologic malignanciesFour oral presentations highlighting data evaluating epcoritamab for the treatment of relapsed/refractory (R/R) la...
November 3, 2022
03.11.2022 - Media Release Copenhagen, Denmark, November 3, 2022 Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody-CD3xCD20) in a variety of treatment settings and hematologic ...
November 3, 2022
Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody-CD3xCD20) in a variety of treatment settings and hematologic malignancies
October 28, 2022
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for...
October 28, 2022
Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for epcoritamab European Medicines Agency (EMA) has validated Marketing Authorization Application
June 30, 2022
Company Announcement COPENHAGEN, Denmark; June 30, 2022 – Genmab A/S (Nasdaq: GMAB) today announced its intent to submit a biologics license application...
June 11, 2022
Epcoritamab demonstrated clinically meaningful efficacy in challenging to treat, highly refractory LBCL patients, including patients previously treated with chimeric antigen receptor (CAR) T-cell therapyTotal patient population achieved overall response rate (ORR) of 63 percent and complete response (CR) of 39 perce...
June 11, 2022
Epcoritamab demonstrated clinically meaningful efficacy in challenging to treat, highly refractory LBCL patients, including patients previously treated with chimeric antigen receptor (CAR) T-cell
January 21, 2022
Background Glioma is a lethal primary tumor of central nervous system. Ferroptosis is a newly identified form of necrotic cell death. Triggering ferroptosis has shown potential to eliminate aggressive tumors. GPX7, a member of glutathione peroxidase family (GPXs), has been described to participate in oxidative stress and tumorigenesis. However, the biological functions of GPX7 in glioma are still unknown. Methods Bioinformatics method was used to assess the prognostic role of GPX7 in glioma. CCK...
January 16, 2022
Contrary to the negative soy information floating about in today’s technological world, the scientific consensus shows soy is ...